Simulation-Based Exosome Nanocarrier Model for Targeted Opioid Analgesia

preprint OA: closed
Full text JSON View at publisher

Abstract

Abstract Background: Conventional opioids provide effective analgesia but cause systemic adverse effects due to widespread distribution and short duration. This study presents a simulation-based framework for exosome-mediated opioid delivery designed to prolong analgesia while minimizing off-target exposure. Methods: Exosome loading, release kinetics, and targeting were modeled using data from mesenchymal stem cell–derived exosomes and validated pharmacokinetic–pharmacodynamic (PK–PD) relationships. Simulations incorporated RGD peptide functionalization for enhanced wound-site targeting and modeled opioid release under physiological (pH 7.4) and acidic (pH 5.5) environments. A conceptual postoperative pain model was used to predict analgesic duration, biodistribution, and safety versus free opioids. Results: Simulated exosome–opioid systems exhibited sustained release (~75 % at 24–36 h) and prolonged analgesia (~8 h vs. ~2 h for free opioids). RGD functionalization increased local accumulation and reduced modeled brain exposure by ~40 %. Simulated plasma opioid levels decreased by ~30–50 %, suggesting reduced respiratory depression risk. Conclusions: The computational findings support exosome-mediated opioid delivery as a promising approach for localized, sustained analgesia with improved safety. The framework provides a quantitative basis for future experimental validation.
Full text 10,627 characters · extracted from preprint-html · click to expand
Simulation-Based Exosome Nanocarrier Model for Targeted Opioid Analgesia | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Simulation-Based Exosome Nanocarrier Model for Targeted Opioid Analgesia Zhuofan Shen This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7939584/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Conventional opioids provide effective analgesia but cause systemic adverse effects due to widespread distribution and short duration. This study presents a simulation-based framework for exosome-mediated opioid delivery designed to prolong analgesia while minimizing off-target exposure. Methods: Exosome loading, release kinetics, and targeting were modeled using data from mesenchymal stem cell–derived exosomes and validated pharmacokinetic–pharmacodynamic (PK–PD) relationships. Simulations incorporated RGD peptide functionalization for enhanced wound-site targeting and modeled opioid release under physiological (pH 7.4) and acidic (pH 5.5) environments. A conceptual postoperative pain model was used to predict analgesic duration, biodistribution, and safety versus free opioids. Results: Simulated exosome–opioid systems exhibited sustained release (~75 % at 24–36 h) and prolonged analgesia (~8 h vs. ~2 h for free opioids). RGD functionalization increased local accumulation and reduced modeled brain exposure by ~40 %. Simulated plasma opioid levels decreased by ~30–50 %, suggesting reduced respiratory depression risk. Conclusions: The computational findings support exosome-mediated opioid delivery as a promising approach for localized, sustained analgesia with improved safety. The framework provides a quantitative basis for future experimental validation. Drug Discovery, Design, & Development Pharmacokinetics Drug Delivery Pharmacodynamics Exosomes nanocarriers Computational Pharmacology Opioid analgesia PK-PD modelling Targeted Drug Delivery translational pharmacology Full Text Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7939584","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":534443022,"identity":"ae9f64fe-c9d0-4ca5-b6ac-774a97d42c67","order_by":0,"name":"Zhuofan Shen","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYDACdiBmbGBg4Gc4fPDBByCHjZ2QFmaoFsnGY8mGM0BamInVYnD4jJo0D0wEH+BvZj4m+XOHTR7DsTPMxja/tsnzMTMwfviYg1uLxGG2ZGPeM2nFjD1nDz7O7btt2MbMwCw5cxseaw7zGD5mbDuc2CxxLtk4t+c2I1ALGzMvHi3yh/k/HPzZ9j+xTf6NmbRlz217gloMDvMwPuBtO5DYw3DGTJrhx+1EgloMD7MZG/O2JSfOYAAGcm/D7eQ2ZsZmvH6RO978TPJnm13i/gPAqPzx57bt/Pbmgx8+4vM+CmBsA5MNxKoHgT+kKB4Fo2AUjIKRAgCJS1W+IzyL0QAAAABJRU5ErkJggg==","orcid":"","institution":"University of Debrecen, Department of Molecular Biotechnology, Debrecen, Hungary","correspondingAuthor":true,"prefix":"","firstName":"Zhuofan","middleName":"","lastName":"Shen","suffix":""}],"badges":[],"createdAt":"2025-10-24 16:40:00","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-7939584/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7939584/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":94490030,"identity":"f4f9d7c8-de66-4cfc-baf1-3a65f74317be","added_by":"auto","created_at":"2025-10-27 17:07:03","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":622373,"visible":true,"origin":"","legend":"","description":"","filename":"1721771Manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7939584/v1_covered_f2327e22-6559-4329-b1fb-2ad28bba38d3.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cem\u003eSimulation-Based Exosome Nanocarrier Model for Targeted Opioid Analgesia\u003c/em\u003e\u003c/p\u003e","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"University of Debrecen, Department of Molecular Biotechnology, Debrecen, Hungary","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Exosomes, nanocarriers, Computational Pharmacology, Opioid analgesia, PK-PD modelling, Targeted Drug Delivery, translational pharmacology","lastPublishedDoi":"10.21203/rs.3.rs-7939584/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7939584/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eBackground: Conventional opioids provide effective analgesia but cause systemic adverse effects due to widespread distribution and short duration. This study presents a simulation-based framework for exosome-mediated opioid delivery designed to prolong analgesia while minimizing off-target exposure. Methods: Exosome loading, release kinetics, and targeting were modeled using data from mesenchymal stem cell–derived exosomes and validated pharmacokinetic–pharmacodynamic (PK–PD) relationships. Simulations incorporated RGD peptide functionalization for enhanced wound-site targeting and modeled opioid release under physiological (pH 7.4) and acidic (pH 5.5) environments. A conceptual postoperative pain model was used to predict analgesic duration, biodistribution, and safety versus free opioids. Results: Simulated exosome–opioid systems exhibited sustained release (~75 % at 24–36 h) and prolonged analgesia (~8 h vs. ~2 h for free opioids). RGD functionalization increased local accumulation and reduced modeled brain exposure by ~40 %. Simulated plasma opioid levels decreased by ~30–50 %, suggesting reduced respiratory depression risk. Conclusions: The computational findings support exosome-mediated opioid delivery as a promising approach for localized, sustained analgesia with improved safety. The framework provides a quantitative basis for future experimental validation.\u003c/p\u003e","manuscriptTitle":"Simulation-Based Exosome Nanocarrier Model for Targeted Opioid Analgesia","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-27 16:02:38","doi":"10.21203/rs.3.rs-7939584/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8838995d-d2ad-400c-b906-0ce4f05adef6","owner":[],"postedDate":"October 27th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":56826779,"name":"Drug Discovery, Design, \u0026 Development"},{"id":56826780,"name":"Pharmacokinetics"},{"id":56826781,"name":"Drug Delivery"},{"id":56826782,"name":"Pharmacodynamics"}],"tags":[],"updatedAt":"2025-10-27T16:02:38+00:00","versionOfRecord":[],"versionCreatedAt":"2025-10-27 16:02:38","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7939584","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7939584","identity":"rs-7939584","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00